1. Clinical Overview
A sterile, topical ophthalmic solution combining a short-acting antimuscarinic cycloplegic agent (Cyclopentolate) with a potent corticosteroid (Dexamethasone). It is primarily used for diagnostic and therapeutic purposes in ophthalmic inflammatory conditions requiring mydriasis and cycloplegia. The combination provides rapid pupil dilation and paralysis of accommodation while simultaneously suppressing inflammation, preventing synechiae formation, and reducing pain and photophobia.
| Onset | Duration | Bioavailability |
|---|---|---|
| Cyclopentolate: Mydriasis begins within 15-30 minutes, maximal cycloplegia in 30-60 minutes. Dexamethasone: Anti-inflammatory effects begin within hours, peak effect in 1-2 days. | Cyclopentolate: Mydriasis lasts 6-24 hours; cycloplegia lasts up to 24 hours, but accommodation typically recovers within 6-12 hours in adults. Dexamethasone: Anti-inflammatory effect persists for the duration of therapy. | Topical ocular. Systemic absorption is minimal but can occur via nasolacrimal drainage and conjunctival/ nasal mucosal absorption. |
2. Mechanism of Action
Cyclopentolate competitively blocks acetylcholine at the muscarinic receptors of the sphincter pupillae and ciliary muscles, causing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). Dexamethasone binds to cytoplasmic glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, thereby reducing the synthesis of prostaglandins, leukotrienes, and other inflammatory mediators. It also stabilizes lysosomal membranes and inhibits migration of inflammatory cells.
3. Indications & Uses
- Pre-operative and post-operative management in cataract surgery
- Treatment of non-infectious anterior uveitis (iritis, iridocyclitis)
- Prevention and breaking of posterior synechiae in inflammatory eye conditions
- Diagnostic procedures requiring cycloplegic refraction (especially in children)
4. Dosage & Administration
Adult Dosage: 1 drop instilled into the conjunctival sac of the affected eye(s). For inflammation: Usually 1 drop every 4 to 6 hours. For mydriasis/cycloplegia: 1 drop, may repeat after 5-10 minutes if needed. Duration should not exceed 10-14 days without re-evaluation.
Administration: Wash hands. Tilt head back. Gently pull lower eyelid to form a pouch. Instill prescribed number of drops. Close eyes gently for 1-2 minutes. Apply gentle pressure on the nasolacrimal duct (inner corner of eye) for 1-2 minutes to minimize systemic absorption. Do not touch dropper tip to any surface. Wait at least 5-10 minutes before instilling any other eye drops.
5. Side Effects
Common side effects may include:
- Transient stinging/burning on instillation
- Blurred vision (due to cycloplegia)
- Photophobia
- Pupillary dilation
- Increased intraocular pressure (mild, transient)
- Dry mouth (systemic anticholinergic effect)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other Anticholinergic Drugs (e.g., Atropine, Homatropine, Tropicamide) | Additive cycloplegic and mydriatic effects; increased systemic anticholinergic side effects. | Major |
| Systemic Corticosteroids (e.g., Prednisolone) | Increased risk of systemic corticosteroid side effects and HPA axis suppression. | Moderate |
| Phenylephrine or other Sympathomimetics | Additive mydriatic effect. | Moderate |
| Cholinergic Agonists (e.g., Pilocarpine, Carbachol) | Antagonizes the miotic effect; may reduce efficacy in glaucoma. | Moderate |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin) | May increase systemic levels of dexamethasone, increasing side effect risk. | Moderate |
7. Patient Counselling
- DO wash hands before use.
- DO apply nasolacrimal duct pressure for 1-2 minutes after instillation.
- DO wait at least 5 minutes before using other eye drops.
- DO NOT touch the dropper tip to eye or any surface.
- DO NOT wear contact lenses during treatment.
- DO NOT drive or operate machinery until vision clears.
- DO inform all doctors about this medication use.
8. Toxicology & Storage
Overdose: Topical: Severe blurred vision, photophobia, extreme pupil dilation. Systemic (esp. in children): Tachycardia, hyperthermia, dry skin, CNS excitation (restlessness, hallucinations, seizures) followed by depression, circulatory collapse, respiratory failure.
Storage: Store at controlled room temperature (15°C to 25°C). Protect from light. Do not freeze. Keep the bottle tightly closed. Keep out of reach of children. Discard the bottle 4 weeks after opening to prevent contamination.